Showing 6871-6880 of 20410 results for "".
Nutrition and the Gut-Brain Connection in Schizophrenia
https://reachmd.com/programs/frontlines-schizophrenia/nutrition-gut-brain-connection-schizophrenia/54157/What if food could influence brain function in schizophrenia? Emerging research into the gut–brain connection suggests that inflammation, immune responses, and cellular energy metabolism may play a meaningful role in psychiatric symptoms—and that targeted dietary strategies could offer new therapeutThe Social Brain in Schizophrenia
https://reachmd.com/programs/frontlines-schizophrenia/the-social-brain-in-schizophrenia/54155/Social dysfunction is a core and often early feature of schizophrenia that affects how individuals interpret social cues, regulate emotions, and engage with others in daily life. Advances in social processes and neuroscience have identified brain networks involved in emotion recognition and mentalizTracking Disease Progression in ATTR-CM
https://reachmd.com/programs/on-the-frontlines-of-attr-cm/tracking-disease-progression-in-attr-cm/49037/Disease progression in transthyretin amyloid cardiomyopathy (ATTR-CM) isn’t as straightforward as it once seemed. While newer therapies are helping patients live longer and better, recognizing when the disease is subtly worsening requires more than waiting for a hospitalization—it means paying attenAdvancing Relapse Prediction in Pediatric AML Through Genomic MRD
https://reachmd.com/programs/clinicians-roundtable/relapse-prediction-pediatric-aml-genomic-mrd/54352/Emerging research suggests genomic minimal residual disease (MRD) could be a more sensitive and stable approach to predicting relapse in pediatric acute myeloid leukemia (AML). Ryan Quigley sits down with Dr. Amanda Winters to learn more about how this method could aid in earlier interventioTreating Hair Loss and Thinning in men over 50
https://reachmd.com/series/skin-minute/heather-woolery-lloyd-md-skin-minute/56411/Heather Woolery-Lloyd, MD, FAAD, Chief Medical Advisor for Nutrafol, discusses the issue of hair loss and thinning in men over 40 and a new solution for treatment.The Burden of Cognitive Dysfunction in Multiple Sclerosis
https://reachmd.com/programs/neurofrontiers/the-burden-of-cognitive-dysfunction-in-multiple-sclerosis/54238/Cognitive impairment affects a significant portion of patients with multiple sclerosis and can impact academic and professional performance. Hear Dr. Christopher Lock discuss how multiple sclerosis-related cognitive changes may present in practice, and how timely evaluation and supportive interventiStrategies to Safeguard Brain Health in MS
https://reachmd.com/programs/neurofrontiers/strategies-to-safeguard-brain-health-in-ms/54774/Cognitive changes are a major concern for patients living with multiple sclerosis (MS), underscoring the importance of proactive brain health strategies. Join Dr. Christopher Lock as he explores practical approaches to preserving cognitive function and discusses the evolving therapeutic landscape aiRethinking Progression in Multiple Sclerosis
https://reachmd.com/programs/neurofrontiers/rethinking-progression-in-multiple-sclerosis/54235/Even with a growing arsenal of disease-modifying therapies, many patients with multiple sclerosis continue to accumulate disability independent of relapses. Axonal injury, incomplete remyelination, and compartmentalized inflammation within the central nervous system are now recognized as key driversWho’s Missing from Multiple Sclerosis Research?
https://reachmd.com/programs/neurofrontiers/diversity-equity-inclusion-multiple-sclerosis-research/54236/Multiple sclerosis (MS) research is evolving, but important gaps remain in how well studies reflect the diversity of people living with the disease. To address this gap, a recent study identified practical, consensus-driven priorities for advancing equity, diversity, and inclusion across MS researchCan AI Transform How We Diagnose ATTR-CM?
https://reachmd.com/programs/on-the-frontlines-of-attr-cm/can-ai-transform-how-we-diagnose-attr-cm/49039/Artificial intelligence (AI) is reshaping how clinicians identify transthyretin amyloid cardiomyopathy (ATTR-CM), offering new opportunities to improve early recognition and diagnostic accuracy. Joining Ryan Quigley to discuss the evolving non-biopsy diagnostic pathway and the growing role of AI in